Search clinical trials for: Insulin degludec, Tresiba

Total 2843 results

University of Padova
Azienda Ospedaliera di Padova

Completed

Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes (Basal21)

Type 1 Diabetes Mellitus

Italy
Novo Nordisk A/S

Enrolling by invitation

A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level (DEAL-2)

Diabetes Mellitus, Type 2

Saudi Arabia
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia (UPDATES)

Diabetes Mellitus, Type 2

Saudi Arabia
LMC Diabetes & Endocrinology Ltd.

Unknown

Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered (FIT Untethered)

Type 1 Diabetes Mellitus

Canada
Sunshine Lake Pharma Co., Ltd.

Completed

A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

Type 2 Diabetes

China
Merete Bechmann Christensen
Novo Nordisk A/S

Unknown

Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study

Type 2 Diabetes Mellitus

Denmark
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

Type 2 Diabetes

China
University of Washington

Completed

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose (GLIDING)

Type 1 Diabetes

United States
Nordsjaellands Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (HypoDeg)

Type 1 Diabetes Mellitus | Nocturnal Hypoglycemia | Recurrent Severe Hypoglycaemia

Denmark
Weill Cornell Medical College in Qatar
Novo Nordisk A/S

Terminated

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Type2 Diabetes

Qatar
Sansum Diabetes Research Institute
Novo Nordisk A/S

Completed

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. (SafrTravlT1D)

Diabetes Mellitus, Type 1

United States
The Cleveland Clinic
Novo Nordisk A/S

Completed

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D)

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (SWITCH PRO)

Diabetes Mellitus, Type 2

United States, Slovakia, Canada, South Africa, Puerto Rico, Poland
Novo Nordisk A/S

Completed

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Terminated

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (TRENT)

Type 2 Diabetes Mellitus | Renal Impairment

United States, Czechia, Hungary, Poland, Serbia
Mannkind Corporation

Completed

Afrezza With Basal Combination (ABC)

Type 1 Diabetes

United States
Fundación Pública Andaluza para la Investigación...

Completed

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (INEOX)

Type 1 Diabetes Mellitus

Spain
Novo Nordisk A/S

Completed

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Emory University
Novo Nordisk A/S

Completed

IDegLira HIGH Trial

Diabetes Mellitus

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Time in Range | HbA1c | Type 1 Diabetes Mellitus With Diabetic Gastroparesis

China
Emory University
Novo Nordisk A/S

Completed

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Sanofi

Completed

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist (BRIGHT)

Diabetes Mellitus, Type 2

Israel, Czechia, Greece, Italy, United States, Bulgaria, Croatia, Denmark, France, Hungary, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
Sanofi

Completed

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (inRange)

Type 1 Diabetes Mellitus

Turkey, Netherlands, Brazil, United States, Germany, Hungary, United Kingdom
University of Guadalajara

Completed

Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus (Diabetes)

Type 2 Diabetes Mellitus

Mexico
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
Novo Nordisk A/S

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (Reach-Control)

Diabetes Mellitus, Type 2

Germany, Spain, Brazil, France, Ireland, Romania, United Kingdom
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)

Diabetes Mellitus, Type 2

Italy, Ireland, Spain, Greece, Finland, Romania, Brazil, United Kingdom, France, Switzerland
Novo Nordisk A/S

Completed

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Austria, Norway, Algeria
Novo Nordisk A/S

Completed

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

India, Denmark, Sweden, Malaysia, Poland, Turkey, Finland, Australia, Thailand, Taiwan
Novo Nordisk A/S

Completed

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

Diabetes
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)

Diabetes Mellitus, Type 2

United States, Mexico, Puerto Rico, Canada, Denmark, France, Austria, Taiwan, Czechia, Brazil, China, Argentina
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Novo Nordisk A/S

Completed

Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects

Healthy | Diabetes

Germany
Yale University

Completed

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark

3

Subscribe